In AML/MDS patients with prolonged neutropenia and HSCT patients with GVHD...
The only azole indicated for prophylaxis against both invasive Aspergillus and Candida fungal infections1–3
NOXAFIL injection, delayed-release tablets, and oral suspension are indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy. NOXAFIL injection is indicated in patients 18 years of age and older. NOXAFIL delayed-release tablets and oral suspension are indicated in patients 13 years of age and older.
NOXAFIL oral suspension is indicated for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole.
References: 1. Sporanox [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2014. 2. Diflucan [prescribing information]. New York, NY: Pfizer Inc; 2014. 3. Vfend [prescribing information]. New York, NY: Pfizer Inc; 2014.
Please orient your device to the portrait position to return to the site.
You are about to leave Merck ConnectTM
You are now leaving Merck Connect for another Merck Web site. To return to the page you were viewing, click "Close."
To continue, click "OK."OK